CI&T CINT 深 沪
已收盘 10-16 16:00:00 美东时间
3.02
-0.010
-0.33%
华盛通- 最 高3.07
- 今 开3.03
- 成交量 9.40万股
- 最 低 3.00
- 昨 收 3.03
- 总市值 3.87亿
- 52周最高 5.80
- 市盈率 静 9.92
- 换手率 0.07%
- 52周最低 2.80
- 委 比 0.00%
- 总股本 1.28亿
- 历史最高 22.50
- 量 比 1.32
- 振 幅 2.31%
- 历史最低 2.80
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CI&T Inc /Brazil收跌0.33%，成交额28.39万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
今天 06:18
CI&T Earnings Call: Growth Surges, Margins Invested
Ci&T, Inc. (($CINT)) has held its Q2 earnings call. Read on for the main hi...
08-21 08:27
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
UBS Maintains Buy on CI&T, Lowers Price Target to $6.2
UBS analyst Leonardo Olmos maintains CI&T (NYSE:CINT) with a Buy and lowers the price target from $7.2 to $6.2.
08-12 21:32
CI&T shares are trading lower after the company reported mixed Q2 financial results.
CI&T shares are trading lower after the company reported mixed Q2 financial results.
08-12 04:48
CI&T Q2 Adj. EPS $0.07 Misses $0.09 Estimate, Sales $142.820M Beat $139.632M Estimate
CI&T (NYSE:CINT) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.09 by 22.22 percent. This is a 22.22 percent decrease over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $142.820 million which beat...
08-12 04:16
CI&T Raises FY2026 Sales Guidance from $555.800M-$575.300M to $565.500M-$577.800M vs $569.840M Est
CI&T (NYSE:CINT) raises FY2026 sales outlook from $555.800 million-$575.300 million to $565.500 million-$577.800 million vs $569.840 million estimate.
08-12 04:13
CI&T Q3 Revenue expected to be more than $145.700M vs $144.560M Est
CI&T (NYSE:CINT) Q3 Revenue expected to be more than $145.700M vs $144.560M Est
08-12 04:12
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Wedbush Downgrades CI&T to Neutral, Lowers Price Target to $4
Wedbush analyst Steven Wahrhaftig downgrades CI&T (NYSE:CINT) from Outperform to Neutral and lowers the price target from $7 to $4.
07-21 21:29
